AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

The FDA also granted approval to AstraZeneca’s another BTK inhibitor Calquence in combination with standard-of-care chemoimmunotherapy for previously untreated mantle cell lymphoma. The approval ...

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...